Objectives: To investigate the effects of long-term treatment with a new enteral formula low in carbohydrates and high in monounsaturated fatty acids (MUFAs), in comparison with a standard formula, on glycaemic control in tube-fed type II diabetic patients. Design: Randomised, double-blind, controlled, multi-centre trial. Setting: Early rehabilitation centres, primary care and nursing facilities. Subjects: A total of 78 patients with insulin-treated type II diabetes with HbA 1C Z7.0% and/or fasting blood glucose 46.66 mmol/l, who required enteral tube feeding due to neurological dysphagia. Interventions: Patients received 113 kJ (27 kcal)/kg of body weight of either test feed or an isoenergetic, isonitrogenous enteral formula (control) for 12 weeks. Glycaemic control (total daily insulin dosage (IU), fasting blood glucose, and HbA 1C ) and gastrointestinal tolerance were monitored daily. Results: After 12 weeks, median values for changes from baseline were as follows (test group vs control group, 'data as available' analysis): total daily IUs À6.0 vs 0.0 (P ¼ 0.0024), fasting blood glucose (mmol/l) À1.59 vs À0.08 (P ¼ 0.0068); HbA 1C (%) À0.8 vs 0.0 (P ¼ 0.0016). Both formulas were tolerated comparably. Conclusions: This study indicates that in tube-fed insulin-treated type II diabetic patients, the new low-carbohydrate, high MUFA formula results in a more effective glycaemic control than the standard diet, while being comparable in safety.
Introduction
The major goal of diabetes management is to achieve and maintain optimum glycaemic control, thereby preventing or delaying associated long-term and acute complications (Coulston, 2000 ; American Diabetes Association (ADA), 2001; Franz et al, 2004; Schafer et al, 2004) . In diabetic patients with cerebral damage and dysphagia due to stroke, glycaemic control is often complicated by altered physiological responses and reduced physical activity, resulting in more frequent hypo-and hyperglycaemia (Morley & Perry, 1991; Roth et al, 2002; Hofman et al, 2004; Schafer et al, 2004) .
Guidelines for the nutritional management of diabetes have changed considerably, emphasising in the last years avoidance of foods that cause an exaggerated glycaemic response (ie foods with a high glycaemic index) (American Diabetes Association (ADA), 2000; Coulston, 2000 ; European Association for the Study of Diabetes (EASD), 2000; Connor et al, 2003; del Carmen Crespillo et al, 2003; Parhofer et al, 2003; Franz et al, 2004; Schafer et al, 2004) . In light of this, carbohydrate-modified enteral diets with reduced glycaemic indices have been developed (Haslbeck et al, 1995; Ha & Lean, 1998 ; American Diabetes Association (ADA), van Drunen et al, 2003; Franz et al, 2004; Hofman et al, 2004) . Although these diets may reduce nonfasting hyperglycaemia, the ability of type II diabetes mellitus (DM) patients to achieve long-term glycaemic benefit has been questioned (Ha & Lean, 1998 ; European Association for the Study of Diabetes (EASD), 2000; American Diabetes Association (ADA), 2002; Connor et al, 2003; Parhofer et al, 2003; Franz et al, 2004) . As type II DM is also a disorder of lipid metabolism (Wright, 2000) , formulas enriched with monounsaturated fatty acids (MUFAs) have been recommended as a strategy to limit intake of polyunsaturated fatty acids (PUFAs) and saturated fatty acids (SFAs) (Fürst, 1998 ; American Diabetes Association (ADA), 2002; Parhofer et al, 2003; Hofman et al, 2004) . High MUFA content may increase HDL-and decrease LDL-cholesterol, triacylglycerols, and total cholesterol concentrations, and may improve lipid and glycaemic control (American Diabetes Association (ADA), 2002; Parhofer et al, 2003) .
The optimal diet for persons with diabetes, regardless of whether or not it is administered through tube feeding, has long been a subject of controversy (Eckel, 2004; Gerhard et al, 2004) . The evidence for beneficial effects from special enteral formulas in tube-fed insulin-treated patients with type II DM is mainly based on short-term studies (American Diabetes Association (ADA), 2002; Parhofer et al, 2003; Hofman et al, 2004) . It still has to be established whether or not long-term use (1-3 months) of special diabetic enteral formulas can result in improved glycaemic control.
The objectives of this study were to evaluate if a better glycaemic control in tube-fed type II diabetes patients could be achieved during long-term treatment with a new diseasespecific, low-carbohydrate, very-high-MUFA enteral formula, compared with a standard formula. Secondary objectives were to ascertain the safety and patient tolerance of the formulations. The results of Stage 1 of this study are given.
Methods

Subjects
Selection criteria were age 40 y or older, insulin-treated type II DM with HbA 1C Z7.0% and/or fasting blood glucose concentrations 46.66 mmol/l (whole blood, enzymatic method, auto-analyser), and indication for tube feeding due to dysphagia caused by neurological disorders. Exclusion criteria were: type I DM, known allergy against ingredients of study diets, intake of other enteral or oral nutrition, parenteral nutrition, significant renal, hepatic or heart disease, and systemic glucocorticoid therapy within 2 weeks before and/or after study admission.
Patients were recruited in Germany and Denmark in four early rehabilitation departments, one nursing home, and one internal medicine department.
Ethics
The study conformed to good clinical practice guidelines and followed the recommendation of the Declaration of Helsinki. The protocol was approved by the local ethics review boards. Potentially eligible patients were given detailed information about the study and were asked to give written agreement to participate. Eligible patients were then randomly allocated, in a double-blinded manner, to receive treatment with either the test or control diet.
Study design
The study was performed as a randomised, prospective, controlled, double-blind, multi-centre trial, planned as a two-stage adaptive procedure.
Interventions
The test solution Diben (Fresenius Kabi Deutschland GmbH) is a nutritionally complete, balanced tube feed for enteral nutrition (EN) with 37% energy as carbohydrates (94.5 g starch þ 24 g fructose þ o6.8 g maltodextrins/1500 ml), 45% energy as fat (thereof 32% MUFA), and 18% as protein. Therefore, Diben complies with the current recommendations of the ADA . It also contains dietary fibre, high amounts of antioxidants (per 1500 ml: b-carotene 10 mg, Vitamin E 100 mg TE, Vitamin C 250 mg, flavonoids from green tea leaves 300 mg), and chromium (400 mg/ 1500 ml). The control solution was formulated for the study as an isoenergetic, isonitrogenous enteral diet with 52% energy as carbohydrates (175.2 g maltodextrins/1500 ml), 30% energy as total fat (thereof 17% MUFA), 18% as protein, dietary fibre, lower amounts of antioxidants, and a standard concentration of chromium (100 mg/1500 ml). This formulation represents the standard enteral formula common in most clinical settings. A detailed description of the composition of both diets is given in Appendix A.
Study diets were administered continuously by nasogastral or percutaneous endoscopic gastrostomy (PEG) tube, starting in the morning after fasting blood glucose was recorded, and the rate of administration was adapted to the patient's tolerance. An 8-h break in nutrition administration was observed before taking blood samples for fasting blood glucose.
Patients received 30 ml/kg body weight (BW) ( ¼ 113 kJ (27 kcal)/kg BW) of the diets per day, with an upper limit of 2250 ml ( ¼ 8477 kJ (2025 kcal)). The daily volume of the diets and the additional daily fluid administration were recorded.
Specific objectives and hypothesis
We tested the hypothesis that in tube-fed insulin-treated type II DM patients the specially formulated enteral diet can have a positive influence on glycaemic control (expressed as a reduction in insulin requirement and unchanged or lower blood glucose levels), when compared with a standard enteral diet. Thus, the following primary and secondary outcome and safety criteria were investigated:
Primary criteria of efficacy: The primary criteria of efficacy were operationalised in the final statistical analysis plan (final SAP) as follows:
Total daily insulin requirement as changes from baseline of the means of the 14-day-intervals 43-56 and 71-84, missing values replaced by the last observed value (last value carried forward (LVCF)), baseline defined as mean of days 2, 3, and 4. Fixed combinations of longand short-acting insulin (Huminsulin s Profil III 40 (Lilly) or Insulin Actraphane s HM 30/70 (Novo Nordisk)) were used. Based on a continuous application of EN, no injection-nutrition intake-time period was required. Insulin dosage (IU) was increased in two IU steps if fasting or afternoon blood glucose were 411.1 mmol/l on two consecutive days, and appropriately reduced by the decision of each investigator. In case of severe hypo-or hyperglycaemia, investigators adjusted IUs accordingly. IU and short-acting adjustments had to be documented daily. Fasting blood glucose (between 0630 and 0730 h after a fasting of 8 h; by the Precision Xtra test stripes system (Abbott Diagnostika, Wiesbaden, Germany)) as changes from baseline of the means of the 14-day intervals 43-56 and 71-84 (LVCF), baseline defined as mean of days 2, 3, and 4. Afternoon blood glucose (between 1630 and 1730 h after a continuous application of study diets for a period of at least 2.5 h) as changes from baseline of the means of the 14-day intervals 43-56 and 71-84 (LVCF), baseline defined as mean of days 2, 3, and 4. HDL-/LDL-cholesterol index as changes from baseline (day 1) of the values at day 56 and 84 (LVCF).
Secondary criteria of efficacy: Glycosylated haemoglobin A (HbA 1C ), C-peptide, triacylglycerol, total cholesterol, LDL cholesterol, and HDL cholesterol.
Safety criteria: Tolerance (nausea, vomiting, and diarrhoea (defined as more than three liquid stools/day)), routine safety laboratory, and adverse events at any time.
Sample size A sample size of 184 patients to be followed for 84 days was calculated to give 90% power to detect a medium-sized (relevant) group difference (Mann-Whitney (MW) estimator ¼ 0.64; nonparametric sample size calculation for the Wilcoxon-MW test using the validated program NNPAR from IDV imputing a type I error of 0.025, one-sided, and a type II error of 0.1). As the difference between groups and the responsiveness of the efficacy criteria were, however, unknown, a two-stage procedure (adaptive design), according to Bauer and Köhne, was chosen (Bauer & Köhne, 1994) . Thus, the first stage of the study should comprise 80 patients. The operating characteristics for stage 1 of the two-stage procedure were defined according to Bauer and Köhne as follows (results of the multivariate Wilcoxon-MW test) (Bauer & Köhne, 1994) : P-value 40.5 stop because of failure, P-value o0.0102 stop because of success, and 0.0102r P-value r0.5 continue with stage 2.
Randomisation
Treatments were randomly allocated to patients, according to a random permuted block scheme. For each centre, a balanced set of treatments was prepared. In accordance with the ICH Guideline E9 (European Agency for the Evaluation of Medicinal Products (EMEA), 1998), the block size was intentionally not given in the study protocol.
The generation of the random code list, including the production of sealed envelopes, was performed in a validated environment using the validated program RANCODE of IDV.
Blinding (Masking)
Both study diets, test and control, were of the same physical size and appearance, including the packaging (500 ml glass bottles). Therefore, all study personnel and participants were blinded to treatment assignment for the duration of the study.
Statistical methods
The set ensemble of the four primary criteria of efficacy at the two points in time (eight variables) was evaluated by means of the directional multivariate Wilcoxon-MW test (Wei-Lachin procedure) with a ¼ 0.025, one-sided (Wei & Lachin, 1984; Lachin, 1992) . This method is the multivariate generalisation of the Wilcoxon-MW test.
The results of the primary efficacy criteria were presented as MW estimators (measure of relevance) and their one-sided 97.5% confidence intervals, so that the direction and quantity of the treatment effects were determined with their precision. The MW estimator is the corresponding standardised effect size of the Wilcoxon-MW test, giving the probability that a randomly chosen patient of the test group is better off than a randomly chosen patient of the control group. The relevant benchmarks for the MW estimator are as follows (Colditz et al, 1988) The univariate P-values were calculated by means of the Wilcoxon-MW test. The summarising P-values were calculated using the generalised multivariate Wilcoxon-MW test (Wei-Lachin procedure) (Lachin, 1992) .
The confirmatory analyses were performed with the intention-to-treat population (full analysis set, missing values replaced by the last value carried forward (LVCF) technique). Preplanned sensitivity analyses were performed with 'data as available'.
A preplanned blind review of the data was performed within the framework of the requirements of the ICH Guideline E9 (European Agency for the Evaluation of Medicinal Products (EMEA), 1998). The statistical analysis plan was reviewed and finalised before the blind was broken. Formal records were kept of when the statistical analysis plan was finalised, as well as when the blind was subsequently broken.
Results
Trial profile, participant flow, recruitment, and data analysis Patients were enrolled from October 2001 to May 2003. A total of 78 patients were randomised. All randomised patients were included in the safety analysis. The primary efficacy analysis (intention-to-treat) included 72 patients. The trial profile and participant flow are shown in Figure 1 .
At 28, 56, and 84 days, the overall percentages of the randomised patients still involved in the study were 83, 69, and 55%. Figure 2 shows the proportion of patients separately for the two treatment groups. The most common reason for premature discontinuation was 'regained swallowing', followed by 'transferred to nursing home'. There are no relevant differences between the two treatment groups with regard to the reasons for premature discontinuation, and there is no indication that any of the discontinuations was related to the efficacy of the test treatment. Thus, the information missing due to patient discontinuation may be considered as if it had been randomly selected for omission.
Baseline data
In all, 42 male patients and 36 female patients participated in the study. Groups were comparable with regard to the demographic baseline criteria. Baseline characteristics of both groups are shown in Table 1 .
In each of the two treatment groups, 28 patients had been receiving standard nutrition (73.7%) and 10 patients specific nutrition (26.3%) before the start of the study treatment (for two patients, information about nutrition before treatment was not available) ( Glycaemic control in tube-fed type II diabetics M Pohl et al treatment groups prior to the study. The total daily energy supply before the beginning of the study was 6593 kJ (1575 kcal) in both groups (medians). Thus, the two groups were very well comparable with regard to nutrition prior to study treatment.
The effect sizes (MW estimator) for the demographic criteria, anamnestic criteria and baseline nutrition criteria, were within the benchmarks and did not show any relevant differences between the two groups (Table 1) . Nevertheless, for the baseline efficacy criteria, some inhomogeneities of relevance were found: For total daily insulin requirement the effect size was lying at the border of relevance (MW ¼ 0.6278), and for afternoon blood glucose the effect size was lying outside the area of not-relevant group differences (MW ¼ 0.6598). For total daily insulin requirement and afternoon blood glucose, the influence of the baseline inhomogeneity upon the efficacy results have been evaluated by means of a stratified analysis of the corresponding primary criterion of efficacy (stratified Wilcoxon test with Cochran-Mantel-Haenszel-Pooling in the sense of a nonparametric adjustment for covariates). There was no indication for bias of the study results (eg final insulin changes from baseline, intention to treat (ITT), LVCF, with adjustment for baseline insulin: P-adjusted ¼ 0.0197 vs P-nonadjusted ¼ 0.0144; final fasting blood glucose changes from baseline, ITT, LVCF with adjustment for baseline insulin: P-adjusted ¼ 0.0484 vs P-unadjusted 0.0626). Table 2 displays the final results of the primary and secondary efficacy criteria of the study. The median change Glycaemic control in tube-fed type II diabetics M Pohl et al from baseline of the average daily insulin requirement at the end of the study ('data as available' analysis) was 0.0 IU in the control group and À6.0 IU in the test group (median percent change: 0.0 vs À12.5%). The effect size denotes a large superiority of the test group (MW ¼ 0.7337, P ¼ 0.0024, one-sided).
Outcomes and estimation
The median change from baseline of the fasting blood glucose at the end of the study ('data as available' analysis) was À0.08 mmol/l in the control group, and À1.59 mmol/l in the test group (median percent change: À0.9 vs À17.8% ) The effect size denotes a large superiority in the test group (MW ¼ 0.7083, P ¼ 0.0068, one-sided). Additionally, Figure 3 shows the effect sizes (MW) and confidence intervals of the changes of the fasting blood glucose as changes from baseline over the study period.
The median change from baseline of the afternoon blood glucose at the end of the study ('data as available' analysis) was 0.02 mmol/l in the control group and À1.23 mmol/l in the test group (median percent change: 0.4 vs À13.0%). The effect size denotes a small superiority of the test group (MW ¼ 0.5779, P ¼ 0.1846, one-sided).
With regard to the fourth primary efficacy criterion, the HDL-/LDL-cholesterol ratio, only marginal group differences were found. The median change from baseline was 0.10 in the control group at the end of the study ('data as available' analysis), and 0.06 in the test group (median percent change: 25.2 vs 25.8%). The effect size denotes a marginal inferiority of the test group at day 84 (MW ¼ 0.4697, P ¼ 0.6363, onesided).
With regard to the secondary efficacy criterion HbA 1C , a marked superiority of the test group was found at the end of the study. The median change from baseline of HbA 1C was 0.0% in the control group ('data as available' analysis), and À0.8% in the test group (median percent change: À1.1 vs À10.0%). The effect size denotes a large superiority of the test group (MW ¼ 0.7657, P ¼ 0.0008, one-sided, exploratory interpretation).
With regard to the secondary efficacy criterion C-peptide, the median change from baseline was 0.23 pmol/l in the control group at the end of the study ('data as available' analysis), whereas the median change under test treatment was À0.04 pmol/l (median percent change: 35.0 vs À3.3%). The effect size denotes a large superiority of the test group (MW ¼ 0.7143, P ¼ 0.0101, one-sided, exploratory interpretation). MW for the remaining secondary criteria is presented below without interpretation, though MW 40.5 indicates higher laboratory values of the Diben group and MW o0.5 lower values: triacylglycerols ¼ 0.3715, total cholesterol ¼ 0.5079, LDL-cholesterol ¼ 0.5216, and HDL-cholesterol ¼ 0.5277; for all P40.05, one-sided, as shown in Table 2 ).
Test-statistical results
Confirmatory results. The result of the confirmatory summarising Wei-Lachin procedure using LVCF replacement of missing values fell short of statistical significance in stage 1 of the planned two-stage-procedure according to Bauer and Köhne (1994) : MW ¼ 0.5422,. lower bound-confidence interval (LB-CI) ¼ 0.4675, P ¼ 0.1229. The effect size (MW) denotes a small superiority of the test feed with regard to the combined efficacy criteria in the ITT population with LVCF (MW ¼ 0.5422). Since the confirmatory P-value of stage 1 is lying between the preplanned benchmarks 0.0102 and 0.5, the study was supposed to be continued with stage 2 as planned.
Sensitivity analyses
Predefined test-statistical results: ITT. The result of the predefined first sensitivity analysis with 'data as available' clearly demonstrates superiority in the test group. The result of the summarising Wei-Lachin procedure is far below the predefined level of significance: MW ¼ 0.6078, LB-CI ¼ 0.5177, P ¼ 0.0095. The effect size of the Wei-Lachin procedure denotes a more than small superiority in the test group with regard to the combined efficacy criteria in the ITT population with data as available. The difference between the 'LVCF' results and the results of the 'data as available' analysis is easily explained by the high dropout rate, leading to a mixture of early values of dropouts (at a time where the effect of the study treatment was not yet fully developed) with final results of completers in the LVCF analysis, thus weakening the observed effect size.
Predefined test-statistical Results: per protocol population (PP). The result of the PP analysis fully agrees with the corresponding result of the ITT analysis.
Safety results
Dosage of study treatment. Both groups were well comparable with regard to the daily dose of the nutritional diets (test group: median 1795.8 ml/day (range 1208-2250 ml/day), Figure 3 The change in fasting blood glucose (changes from baseline) over the study period. LVCF ¼ last value carried forward. Data set: ITT. Univariate MW statistics (MW estimator) and confidence intervals (97.5% confidence intervals, one sided).
Glycaemic control in tube-fed type II diabetics M Pohl et al control group: median 1847.1 ml/day (range 1085-2250 ml/ day), Wilcoxon-MW test, P40.05).
Adverse events
In the test group, one patient suffered from an adverse event which was judged as related to the study treatment (diarrhoea). In the control group, one adverse event was judged as 'possibly related to treatment' (severe hyperglycaemia). An individual listing of the symptoms, severity, relation to study treatment, and outcome of all serious and not serious adverse events during the study period is given in Appendix B.
Routine safety laboratory
No relevant differences were found between the test and control groups with regard to haematology and clinical chemistry.
Tolerance
During the study, 56.4% of the patients in the test group and 53.9% in the control group were without diarrhoea, 61.5% of the test group and 71.8% of the control group were without vomiting, and 82.1% of the patients in the test group and 89.7% of the control group were without nausea.
Discussion
This study indicates that a specific enteral diet can positively influence glycaemic control in tube-fed insulin-treated type II diabetic patients, in comparison with a standard diet higher in carbohydrates and lower in fat. The positive influence on glycaemic control was expressed as a reduction of insulin requirement and improved blood glucose adjustment (fasting blood glucose and HbA 1C ). The tolerance of the tube feeds was comparable in both groups, although there was a nonsignificant trend for a higher rate of abdominally associated adverse events (vomiting and diarrhoea) in the test group. Thus, in stage 1, relevant treatment effects have been evident, in combination with a comparable tolerability.
Possible mechanism and explanations
The reduced insulin requirement in the test group may be interpreted as an effect of the test diet, given that the blood glucose remains unchanged or is lower than in the control group. The study has shown an effect on both criteria, which supports the conclusion of the overall efficacy of the test diet on glycaemic control. Additionally, over the study period, a significant increase in C-peptide plasma levels was found in the control group, compared with a slight decrease in the test group (Table 2) , indicating an increase of endogenous insulin secretion in the control group and a slight suppression in the test group (Alvarsson et al, 2003) . When the lower total daily insulin requirement is taken into consideration, these findings could indicate a better glycaemic control in the test group, resulting from a positive influence on the relationship between endogenous insulin production and insulin resistance (Low et al, 1996; Gumbiner et al, 1998) . The results of the afternoon blood glucose and of the HDL-/LDL-cholesterol index show only marginal group differences. Afternoon blood glucose is influenced by the history of the day, that is, by varying flow rates and interruptions in the administration of the diets, and is thus not as consistent as the fasting blood glucose taken in the morning (Table 2 ). An increase in the HDL-/LDL-cholesterol index was observed in both groups despite the higher amount of total fat in the test diet. In another study, the HDL-/LDL-cholesterol index remained unchanged, while treatment effects were shown only with regard to insulin and blood glucose (Craig et al, 1998) . However, with regard to triacylglycerols, HDL-cholesterol, and LDL-cholesterol, it is clear that the test treatment did not influence the lipid metabolism in a negative way, despite the higher fat content.
The control diet of the study was developed to represent a standard clinical formulation. In comparison, the test diet contained higher concentrations of MUFA (88% more) and total fat (50% more), and less carbohydrates (29% less). The high ratio of MUFA to total fat was selected to limit the amounts of saturated and PUFAs (Coulston, 1998 ; American Diabetes Association (ADA), 2000; Connor et al, 2003; Parhofer et al, 2003; Hofman et al, 2004) . Saturated fats have been shown to have a negative influence on serum cholesterol, and polyunsaturated fats may cause increased lipid peroxidation, and may therefore be more atherogenic (Ha & Lean, 1998; Wright, 2000; American Diabetes Association (ADA), 2002) . There is increasing support for the recommendation that the carbohydrate content of the diet should be reduced, with a concomitant increase in the fat content, largely as MUFA (Wright, 2000) . This recommendation is not, however, without controversy with regard to the nutrition of non-tube-fed persons with diabetes (Eckel, 2004; Gerhard et al, 2004) . A meta-analysis of published studies in non-tube-fed type II diabetes showed that, for every 1% reduction in dietary carbohydrates and increase in MUFA, there was a corresponding reduction in plasma triacylglycerols of almost 1% (Garg, 1998) . In addition to the marked improvement in the lipoprotein profile, there was a significant reduction in fasting plasma glucose, though with no change in plasma insulin levels (suggesting no significant change in insulin sensitivity) (Garg, 1998) . Importantly, there is no evidence from this meta-analysis that high MUFA diets predispose to weight gain, provided that total energy intake is controlled. Furthermore, with tube-fed type II DM patients, weight gain as a result of tube feeding is not a great concern, as these patients tend much more towards malnutrition than obesity (Coulston, 1998; Franz et al, 2004) . In conclusion, the major benefits of the high-MUFA-containing test diet with respect to improved glycaemic control is probably due to the lower carbohydrate content, resulting in a reduction in hyperglycaemia (Ha & Lean, 1998; Wright, 2000) . In addition, the therapeutic concentrations of chromium may play an important role in improving glycaemic control in the test group by increasing insulin sensitivity (Anderson, 2000) .
Comparison with relevant findings from other published studies A number of small studies have addressed the short-term effects of enteral diets on glycaemic response in type II DM. These studies have shown varying results (Stürmer et al, 1994; Golay et al, 1995; Haslbeck et al, 1995; Printz et al, 1997; Sanz-Paris et al, 1998; van Drunen et al, 2003) . A few controlled studies have been published, all having either a very short observation period (o4 weeks) (Mesejo et al, 2003) , a very small number of patients (Low et al, 1996; Gumbiner et al, 1998; McCargar et al, 1998) , or a combination of both deficiencies (Celaya et al, 1992; Low et al, 1996; Gumbiner et al, 1998; McCargar et al, 1998; Böttcher et al, 2000; Mesejo et al, 2003; Hofman et al, 2004) . These studies also have shown varying results (Parhofer et al, 2003) , and none of these adhered to the CONSORT guidelines for randomised controlled trials (Wright, 2000; Moher et al, 2001) . In a pilot study in which tube-fed type II DM patients in long-term residential care received either a high-MUFA or high-carbohydrate nutritional diet (Craig et al, 1998) , there was a clear (though statistically insignificant) tendency towards better metabolic control and lower insulin requirements in the patients on the high-MUFA preparation. In addition, there was a reduction in complications (infections and pressure ulcers) in the high-MUFA group (Craig et al, 1998) .
Implications and limitations of the study Although the predefined confirmatory result of stage 1 of the two-stage procedure concerning the LVCF analysis is not statistically significant (P ¼ 0.1229, confirmatory summarising Wei-Lachin procedure (Wei & Lachin, 1984; Lachin, 1992) ) for the ensemble of the primary efficacy criteria, the result of the summarising Wei-Lachin procedure is smaller than the predefined level of significance (P ¼ 0.0095) in the predefined sensitivity analysis with 'data as available'. The difference between the two results may be attributed to the fact that almost half of the patients dropped out before the final visit (see Figures 1 and 2 ). As expected, the metabolic effect of the test diet increased through the study period (so-called 'growth curve', see Figure 3 ). While the analysis of 'data as available' represents the situation of the patients physically present at the corresponding visit (thus showing strong effects at the final visits), the LVCF analysis represents a mixture of actual values and values from earlier visits of dropout patients (thus representing a mixture of large final effects and weaker early effects of dropout patients). Since the missing values of dropouts are missing at random, that is, they are not efficacy-related, and the dropout pattern is well comparable in both treatment groups, the results of the 'data as available' analysis can be interpreted in this light without introducing a bias. On the other hand, the causes of the high dropout rate are partially grounded in the conditions under which patients were recruited, and could represent a meaningful impact on the study. The investigators recruited patients primarily in departments of early neurological rehabilitation. These tube-fed type II DM patients, in contrast with patients in nursing homes, were under close medical observation, thus guaranteeing the feasibility of the study. Moreover, the patients, because of their severe and sometimes unstable condition, had frequent blood glucose fluctuations. These patients were particularly suitable for the investigation of an influence of the study diet on glycaemic control in correspondence with the current literature (Ha & Lean, 1998; Coulston, 2000; Wright, 2000; American Diabetes Association (ADA), 2002; Parhofer et al, 2003) . One drawback of this, however, is that, because of the recruitment of patients largely from the department of early neurological rehabilitation, the prognosis of the patients could not be foreseen, and many patients did not complete the study, either due to release from the inpatient rehabilitation program ('transfer to nursing home') or due to their regaining of the ability to swallow (see Figures 1 and 2 ).
In addition, as expected from the severity of patient illness, both groups in the study had a relatively high incidence of adverse events and intolerance. Particularly of note were the high rates of vomiting and diarrhoea, both indicators of vegetative instability of the patients. These adverse events might also have been related to the high flow rates of the study diets (200-350 ml/h, including the additional daily liquid requirements). These high flow rates were necessary due to the short daily period of diet application in these critically ill patients. Opportunities for feeding were limited by the patients' participation in various rehabilitation activities during the day, and by the established 8-h fasting period at night. However, similar rates of adverse events were reported in the above-mentioned pilot study (Craig et al, 1998) . Adverse events were not reported in the remaining studies in the literature (Low et al, 1996; Gumbiner et al, 1998; McCargar et al, 1998) .
In conclusion, there is high clinical and biometrical plausibility for the behaviour of the efficacy results in this study.
Overall evidence
The test treatment in tube-fed type II diabetic patients showed relevant effects on total insulin requirements, fasting blood glucose, and HbA 1C , indicating improvements in metabolic control. The study results give strong evidence for the superiority of the test treatment compared with the standard tube feeds for patients with type II DM who need long-term EN. Stage 2 of the adaptive two-stage procedure with adapted primary variables and adjusted sample size is still ongoing. Glycaemic control in tube-fed type II diabetics M Pohl et al
